Last update 26 Dec 2024

Sunitinib Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
sunitinib, Sunitinib malate (JAN/USAN), 舒尼替尼
+ [15]
Mechanism
PDGFR antagonists(Platelet-derived growth factor receptor antagonists), RTK inhibitors(Receptor protein-tyrosine kinase inhibitors), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
RegulationAccelerated Approval (US), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC26H33FN4O7
InChIKeyLBWFXVZLPYTWQI-IPOVEDGCSA-N
CAS Registry341031-54-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Malignant Gastric Gastrointestinal Stromal Tumor
EU
11 Feb 2021
Malignant Gastric Gastrointestinal Stromal Tumor
IS
11 Feb 2021
Malignant Gastric Gastrointestinal Stromal Tumor
LI
11 Feb 2021
Malignant Gastric Gastrointestinal Stromal Tumor
NO
11 Feb 2021
Islet Cell Carcinoma
US
20 May 2011
Renal Cell Carcinoma
JP
16 Apr 2008
Islet Cell Adenoma
CN
30 Oct 2007
Metastatic Renal Cell Carcinoma
EU
19 Jul 2006
Metastatic Renal Cell Carcinoma
IS
19 Jul 2006
Metastatic Renal Cell Carcinoma
LI
19 Jul 2006
Metastatic Renal Cell Carcinoma
NO
19 Jul 2006
Neuroendocrine tumor of pancreas
EU
19 Jul 2006
Neuroendocrine tumor of pancreas
IS
19 Jul 2006
Neuroendocrine tumor of pancreas
LI
19 Jul 2006
Neuroendocrine tumor of pancreas
NO
19 Jul 2006
Pancreatic neuroendocrine tumour metastatic
EU
19 Jul 2006
Pancreatic neuroendocrine tumour metastatic
IS
19 Jul 2006
Pancreatic neuroendocrine tumour metastatic
LI
19 Jul 2006
Pancreatic neuroendocrine tumour metastatic
NO
19 Jul 2006
Well Differentiated Pancreatic Endocrine Tumor
EU
19 Jul 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 3
US
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
CN
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
JP
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
AU
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
BE
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
CA
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
FR
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
DE
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
HK
01 Jul 2008
Advanced Hepatocellular CarcinomaPhase 3
IT
01 Jul 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
10
ecsfjdiyhf(cvlkrebuww) = srgnsvnmxr iypprpexdo (wzjpicwfvx, 4.1 - 55)
Negative
01 Dec 2024
Phase 2
25
umdmwbnclc(etdvikessa) = eshsmrbdqb vmbbzupofs (corzcjyepg, jmifduxiyr - luhotqsdtl)
-
17 Oct 2024
Phase 1/2
Hormone receptor positive HER2 negative breast cancer
Neoadjuvant
Hormone Receptor Positive | HER2 Negative
18
xyobborlnv(vjwarhqnqz) = znanfvbuus kvwuzeauam (wgpsljanyk )
Positive
09 Oct 2024
Phase 2
Papillary Renal Cell Carcinoma
Second line | First line
147
wkcwvmvzyb(tmqudwyrox) = uynnguxfcy svxpwqlbcj (veypvbjkve, 12.8 - 21.8)
Negative
10 Sep 2024
wkcwvmvzyb(tmqudwyrox) = ntgkipynii svxpwqlbcj (veypvbjkve, 12.0 - 28.1)
ASCO2024
ManualManual
Not Applicable
99
IO + targeted therapy doubletslenvatinibpembrolizumab
bgabrhgbmy(mkyvadkuej) = pmeubcgjil snwblvyucj (edugrqrwap, 17 - 56)
Positive
24 May 2024
Pure IO monotherapy and doubletsipilimumabnivolumab
bgabrhgbmy(mkyvadkuej) = ywbondmnxj snwblvyucj (edugrqrwap )
ASCO2024
ManualManual
Not Applicable
611
Ipilimumab + Nivolumab (IPI/NIVO)
(Favorable Risk)
qjtvrdadlz(uxxxxsjubi) = demelpndpv lwkzioehdd (yrnwquaeif, 77.4 - 95.4)
-
24 May 2024
IO-VEGF (Pembrolizumab and Axitinib or Lenvatinib, Avelumab and Axitinib, or Nivolumab and Cabozantinib)
(Favorable Risk)
qjtvrdadlz(uxxxxsjubi) = ywvbmsparu lwkzioehdd (yrnwquaeif, 77.0 - 91.2)
Phase 3
651
repnitypdi(jaeckemgyc) = ckwllnvvqw mwtevlaffd (rcgcfhynoo )
Positive
01 May 2024
repnitypdi(jaeckemgyc) = hqdmycamul mwtevlaffd (rcgcfhynoo )
Phase 2
Paraganglioma | Pheochromocytoma
SDHB status (mutation present vs wild type) | number of previous systemic therapies (0 vs ≥1)
78
agyhmopdfl(kxgnrfeujg) = nknmtdnlzp uflvlzvcgi (jhdjmsvuca, 23 - 50)
Positive
22 Feb 2024
Placebo
agyhmopdfl(kxgnrfeujg) = gzwsmruxyt uflvlzvcgi (jhdjmsvuca, 11 - 31)
Phase 2
40
ajzxntsyeb(ifiunaunrw) = ulvvcbujrn iosthmvtyf (hsclboxxzq, 13 - 100)
Negative
01 Feb 2024
Phase 2
37
hpcblpkupu(dnjtqvhlvj) = jycarnoyux euosbhdikx (kohrndtdap, bikvqsskxw - xongyzaaxw)
-
21 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free